Article info

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial

Authors

  1. Correspondence to Dr Andrew Östör, Emeritus Research, Level 2/1180 Toorak Rd, Camberwell, VIC 3124, Australia; andrewostor{at}gmail.com
View Full Text

Citation

Östör A, Van den Bosch F, Papp K, et al
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial

Publication history

  • Received June 24, 2021
  • Accepted October 12, 2021
  • First published November 23, 2021.
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.